O3-10-4 - The Chemotherapeutic Selection for Pancreatic Cancer Patients with Malignant Ascites

Abstract

Background: Pancreatic cancer(PC) patients(pts) with peritoneal dissemination are poor prognosis. This retrospective study evaluated the prognosis of Gemcitabine(GEM)-based current chemotherapy(G), GEM plus S-1 combination therapy(GS) and single agent of S-1 as 1st line chemotherapy regimen in PC pts with malignant ascites.Methods: This is a retrospective study of PC pts with ascites in the CT image who underwent chemotherapy between 2002 and 2013. We collected data on age, sex, Performance Status(PS), tumor location, other metastasis location, status of ascites, CA19-9, CEA, albumin, CRP. We classified 1st line chemotherapy regimen in G, GS and S-1, and we evaluated 1-year survival rate, progression free survival(PFS), overall survival(OS) for the 3 regimens.Results: A total of 97 pts were included. Median age was 65, males 57%, PS 0-1 91%. The number of pts treated with G, GS, S-1 was 49, 33, 15. The 1-year survival rate of G, GS and S-1 were 18.3%, 21.2% and 53.3%. The median PFS were 106 days, 90 days and 142 days, respectively. The median OS were 196 days, 174 days, 395 days, respectively. The 1-year survival rate of S-1 was significantly better than that of G (P < 0.05).Conclusions: We suggest the selection of S-1 as 1st line chemotherapy regimen in PC pts with malignant ascites might be effective and we need further investigation.